Results from this trial for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019.
Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a combination of savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor) were investigated for the treatment of metastatic papillary RCC.
Although the numbers of patients in this trial were small, the study concluded that the combination of savolitinib and durvalumab appears to be safe and effective in metastatic papillary RCC. In previously untreated patients, response rate was 29% and median progression-free survival was 12 months.